Susan Kantor - 12 Feb 2026 Form 4 Insider Report for Envoy Medical, Inc. (COCH)

Role
Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for Susan J. Kantor pursuant to Power of Attorney filed herewith.
Issuer symbol
COCH
Transactions as of
12 Feb 2026
Net transactions value
+$38,460
Form type
4
Filing time
17 Feb 2026, 16:47:12 UTC
Previous filing
05 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kantor Susan Director C/O ENVOY MEDICAL, INC., 4875 WHITE BEAR PARKWAY, WHITE BEAR LAKE /s/ Andrew Nick as Attorney-in-Fact for Susan J. Kantor pursuant to Power of Attorney filed herewith. 16 Feb 2026 0001673071

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COCH Class A Common Stock Purchase $38,460 +96,150 +123% $0.4000 174,037 12 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COCH Warrant (right to buy) Purchase $0 +57,690 $0.000000 57,690 12 Feb 2026 Class A Common Stock 57,690 $0.4000 Direct F2, F3
transaction COCH Warrant (right to buy) Purchase $0 +96,150 $0.000000 96,150 12 Feb 2026 Class A Common Stock 96,150 $0.4000 Direct F2, F4
holding COCH Stock Option (right to buy) 62,500 12 Feb 2026 Class A Common Stock 62,500 $2.40 Direct F1
holding COCH Stock Option (right to buy) 62,500 12 Feb 2026 Class A Common Stock 62,500 $0.8130 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
F2 Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
F3 The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
F4 The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.